CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis

Company Overview

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases caused by insufficient expression of essential proteins. The company’s approach is designed to increase the body’s production of naturally occurring proteins by activating the transcription of specific genes, potentially addressing the underlying cause of disease rather than only treating symptoms.

CAMP4’s technology platform uses RNA-based gene-activation therapeutics intended to target regulatory regions associated with disease-relevant genes. Its development programs are focused on conditions in which restoring or increasing expression of a functional gene product may provide a therapeutic benefit. The company’s lead program, CMP-CPS-001, is being developed for carbamoyl phosphate synthetase 1 deficiency, a rare inherited disorder that affects the urea cycle and can cause the accumulation of toxic ammonia in the blood.

Based in Cambridge, Massachusetts, CAMP4 Therapeutics was established to advance programmable gene-control medicines for rare and other genetically driven diseases. The company is conducting preclinical and clinical development activities and has focused its initial efforts on rare disorders with significant unmet medical needs. Additional information about its broader pipeline and leadership is limited relative to more established biopharmaceutical companies.

Key Stats

• Today's Range: $3.76 to $4.15
• 50-Day Range: $3.01 to $5.44
• 52-Week Range: $2.85 to $7.75
• Volume: 85,985 shs
• Average Volume: 197,760 shs
• Market Capitalization: $242.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.71
• Consensus Rating: Moderate Buy

CAMP4 Therapeutics Stock Analysis - MarketRank™

CAMP4 Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 121st out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CAMP4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

CAMP4 Therapeutics has a consensus price target of $9.71, representing about 153.0% upside from its current price of $3.84.

Amount of Analyst Coverage

CAMP4 Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CAMP4 Therapeutics are expected to decrease in the coming year, from ($0.57) to ($0.71) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CAMP4 Therapeutics is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CAMP4 Therapeutics is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CAMP4 Therapeutics has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.02% of the float of CAMP4 Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CAMP4 Therapeutics has a short interest ratio ("days to cover") of 3.63, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CAMP4 Therapeutics has recently decreased by 16.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CAMP4 Therapeutics does not currently pay a dividend.

Dividend Growth

CAMP4 Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.07

News Sentiment

CAMP4 Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for CAMP4 Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Selling Shares

Cluster Insider Buying

4 insiders have purchased shares of CAMP4 Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, CAMP4 Therapeutics insiders have sold 2,428.03% more of their company's stock than they have bought. Specifically, they have bought $99,051.00 in company stock and sold $2,504,037.00 in company stock.

Percentage Held by Insiders

21.69% of the stock of CAMP4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

CAMP4 Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CAMP
• CIK: 730255
• Web: www.calamp.com
• Phone: (949) 600-5600
• Fax: 805-856-3857
• Employees: 644
• Year Founded: 1981

Price Target and Rating

• Average Price Target for CAMP4 Therapeutics: $9.71
• High Price Target: $15.00
• Low Price Target: $6.00
• Potential Upside/Downside: +153.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.40 million
• Net Margins: -2,543.74%
• Pretax Margin: -2,543.74%
• Return on Equity: -252.79%
• Return on Assets: -85.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.70
• Quick Ratio: 4.70

Sales & Book Value

• Annual Sales: $3.50 million
• Price / Sales: 68.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.02 per share
• Price / Book: 3.76

Miscellaneous

• Outstanding Shares: 62,750,000
• Free Float: 49,142,000
• Market Cap: $240.96 million
• Optionable: No Data
• Beta: 0.27